By Chris Wack
Hoth Therapeutics' shares surged more than 250% to $3 following positive interim results from its Phase 2a trial of HT-001, aimed at treating skin toxicities from EGFR inhibitors in cancer patients.
The stock hit its 52-week high of $3.08 earlier in the session, and is up more than 100% in the past 12 months.
The New York-based biopharmaceutical company said the trial showed 100% of participants met the primary efficacy endpoint, with significant skin improvement by six weeks. Additionally, 66% experienced reduced pain and itching, enhancing quality of life without needing to reduce EGFRi doses.
Hoth said this is a breakthrough as it avoids such dose reductions, which it says is a common solution to these skin issues.
The trial confirmed no adverse effects, highlighting HT-001's tolerability, said the company.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 07, 2025 10:40 ET (15:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。